Prophylactic and therapeutic drug for nonalcoholic fatty liver disease

Patent metadata

Field	Value
Publication number	US-12042483-B2
Application number	US-202117515945-A
Country	US
Kind code	B2
Filing date	Nov 1, 2021
Priority date	Jan 11, 2017
Publication date	Jul 23, 2024
Grant date	Jul 23, 2024

Abstract

The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) α agonist with a sodium glucose cotransporter 2 (SGLT2) inhibitor, which is to be used for preventing and/or treating nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

First claim

The invention claimed is:

1. A method for treating a liver disease in a human subject suffering from a liver disease selected from nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma, the method comprising: administering to the subject therapeutically effective amounts of pemafibrate or a pharmaceutically acceptable salt thereof and tofogliflozin or a pharmaceutically acceptable salt thereof, wherein the therapeutic effective amounts treat the liver disease.

2. The method of claim 1 wherein the liver disease is nonalcoholic fatty liver disease.

3. The method of claim 1 wherein the liver disease is nonalcoholic steatohepatitis.

4. The method of claim 1 wherein the liver disease is liver cirrhosis.

5. The method of claim 1 wherein the liver disease is hepatocellular carcinoma.

6. The method of claim 1 wherein the subject is identified as suffering from the liver disease.

7. A method for reducing lipid droplet size and ballooning in the liver of a human subject suffering from a liver disease selected from nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma, the method comprising: administering to the subject therapeutically effective amounts of pemafibrate or a pharmaceutically acceptable salt thereof and tofogliflozin or a pharmaceutically acceptable salt thereof, wherein the therapeutic effective amounts reduce the lipid droplet size and ballooning.

8. The method of claim 7 , wherein the liver disease is nonalcoholic fatty liver disease.

9. The method of claim 7 , wherein the liver disease is nonalcoholic steatohepatitis.

10. The method of claim 7 , wherein the liver disease is liver cirrhosis.

11. The method of claim 7 , wherein the liver disease is hepatocellular carcinoma.

Assignees

• Kowa Co

Inventors

• Sasaki Yusuke
• Asahiyama Masato
• Tanaka Toshiya

Classifications

• A61K31/7048

  having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title

• A61K31/7034

  attached to a carbocyclic compound, e.g. phloridzin · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title